Business Wire

Textron Aviation Defense and Thai Aviation Industries Sign Agreement to Support Royal Thai Air Force

19.6.2025 09:30:00 EEST | Business Wire | Press release

Share

During the Paris Air Show, Textron Aviation Defense LLC., a Textron Inc. (NYSE: TXT) company, and Thai Aviation Industries Co., Ltd. signed a Memorandum of Agreement to work together on a sustainment program for the Royal Thai Air Force (RTAF). This program will support RTAF's fleets of Beechcraft T-6TH and AT-6TH aircraft.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618711147/en/

Textron Aviation Defense LLC. and Thai Aviation Industries Co., Ltd. sign a Memorandum of Agreement to sustain Beechcraft T-6TH trainer and AT-6TH light attack aircraft for the Royal Thai Air Force (RTAF)

The Beechcraft T-6TH trainer and AT-6TH light attack aircraft are designed and manufactured by Textron Aviation Defense LLC., a wholly owned subsidiary of Textron Aviation Inc.

Textron Aviation Defense, based in Wichita, Kansas, USA, is the original equipment manufacturer (OEM) for these aircraft. Thai Aviation Industries, located in Bangkok, Thailand, is the prime contractor for this program and has a long history of providing support for RTAF.

“The Beechcraft T-6TH and AT-6TH aircraft strengthen the mutual defense cooperation and relationship between the U.S. and Thailand,” said Tom Webster, vice president, Defense Sales. “This agreement with Thai Aviation Industries ensures the highest level of sustainment support for the RTAF and is an important element of our commitment to the growth of Thailand’s aerospace industry.”

The agreement highlights the strengths of both companies. Textron Aviation Defense brings its expertise as the aircraft's OEM, while Thai Aviation Industries offers its unique position and experience in Thailand.

This collaboration aims to provide long-term support and sustainment for RTAF's aircraft, ensuring a high level of readiness for training and light attack missions. Both companies are committed to working together to deliver the best possible service to RTAF.

About the Beechcraft T-6 Texan II

The Beechcraft T-6 Texan II is the world’s premier military flight trainer. The aircraft’s low acquisition, operating and sustainment costs enable global air forces to fast-track pilot production. With an installed base that more than quadruples its closest competitor, the family of Beechcraft T-6 Texan II aircraft has been the world’s number one Integrated Training System (ITS) for more than 20 years. The Beechcraft T-6 Texan II capitalizes on an active production line with an industry-leading Manufacturing Readiness Level (MRL) rating of 10 as well as a proven supply chain and the affordability of 85 percent parts commonality with the Beechcraft AT-6 Wolverine. To date, the global fleet of more than 1,000 Beechcraft T-6 Texan II aircraft has surpassed 5 million flight hours across 14 nations and two NATO flight schools.

A vital asset, the T-6 empowers global pilot training across the North Atlantic Treaty Organization (NATO) Flight Training program in Canada, the Euro NATO Joint Jet Pilot Training Program (ENJJPT) at Sheppard AFB, Texas and the U.S. Air Force Aviation Leadership Program as well as the U.S. Air Force, Navy, Marine Corps, Army and Coast Guard, the Hellenic Air Force, the Argentine Air Force, the Israeli Air Force, the Royal Air Force, the Iraqi Air Force, the Royal Canadian Air Force, Mexican Navy, the Mexican Air Force, the Royal Moroccan Air Force, the Colombian Air Force, the Royal New Zealand Air Force, the Royal Thai Air Force, Tunisian Air Force and the Vietnam Air Defense Air Force.

About the Beechcraft AT-6 Wolverine

Purpose-built for light attack, counter-insurgency and Countering Violent Extremist Organizations (C-VEO), the high performance, low risk Beechcraft AT-6 Wolverine delivers affordable precision and endurance across operations in austere environments. The aircraft empowers operators with Next Gen Intelligence, Surveillance and Reconnaissance (ISR), the industry's best loitering close air support / precision strike capability, the ability to maintain pressure on targets, and reliable networked battlespace communications and video, linking every sensor to every operator — anytime, anywhere.

The U.S. Air Force completed the aircraft's military type certification and acquired two Beechcraft AT-6E Wolverine in 2020. The Royal Thai Air Force, a key U.S. security ally and operator of one of the most advanced air forces in Asia Pacific, followed in 2021, selecting the Beechcraft AT-6TH Wolverine to support their 41st Wing light attack operations at Chiang Mai Air Base.

About Textron Aviation Defense LLC

With a legacy of thousands of proven Beechcraft and Cessna Integrated Training Systems produced and missionized in America’s Heartland since WWII, military customers turn to Textron Aviation Defense when they need airborne solutions for their critical missions. Provider of the world’s foremost military flight trainer, Textron Aviation Defense equips militaries worldwide and leads in low acquisition, sustainment and training costs. The Beechcraft T-6 Texan II fleet of more than 1,000 aircraft has logged more than 5 million hours across two NATO military flight schools and fourteen countries since 2001. Textron Aviation Defense is a subsidiary of Textron Aviation Inc.

About Textron Aviation

We inspire the journey of flight. For more than 95 years, Textron Aviation has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops and high-performance pistons, to special missions, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable, productive and flexible flight.

For more information, visit www.txtav.com| specialmissions.txtav.com| defense.txtav.com| scorpion.txtav.com.

About Textron Inc.

Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, and Textron Systems.

For more information, visit: www.textron.com.

Certain statements in this press release may project revenues or describe strategies, goals, outlook or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements.

About Thai Aviation Industries Co.,Ltd.

Thai Aviation Industries Co.,Ltd. (TAI) was established by the policy of the Government of Thailand and the Royal Thai Air Force to carry out aircraft maintenance for government agencies and to expand Thailand’s aviation maintenance capabilities to be an international standard aircraft maintenance center. TAI is an approved Thai MRO company that received the privilege from the Public Procurement and Supplies Administrative Act for maintenance support to all states Aircraft.

TAI has played a significant role in the MRO service including the logistics support to all military and commercial aircraft in Thailand for more than 20 years. TAI maintains capabilities in varies Aircraft type such as F-16A/B, C-130H, T-6C, Alpha Jet, Saab 340, BT-67, ATR72-500, S-92A, Cessna 150/152/172/182/208, Bell 121/412 Series, Airbus A320 Series, Boeing B737 Series, Airbus Helicopters (H125/H145/H155/H175), etc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250618711147/en/

Contacts

Media:

Doug Scott
+1.316.347.0116
dscott2@txtav.com
txtav.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.txtav.com%2
F&esheet=54278008&newsitemid=20250618711147&lan=en-US&anchor=txtav.com&index=14&
md5=a4d20496183a3c4dc1f7e6ad19d70f45

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye